A 58-year-old patient came in for her annual hormone reassessment carrying a DEXA her primary care had ordered the week before. T-score at the lumbar spine was -2.3 — osteopenia trending toward osteoporosis. Femoral neck was -1.9. Her PCP had handed her a prescription for alendronate and a brochure about falls prevention. She had not filled it. She wanted to know whether the estradiol patch she had been on for four years was helping or hurting, and what we should do about the bone scan.
The answer was that the patch had slowed but not halted the loss, and her dose was under what her bones needed. We adjusted her transdermal estradiol up modestly, added testosterone at a dose appropriate for women, sorted her vitamin D and calcium intake, and built in a follow-up DEXA at two years. We did not start the bisphosphonate. Her case was not the case for one — yet.
When I evaluate patients for long-term hormone therapy, the bone conversation is one of the most important and most undertaught. The Women's Health Initiative did real damage to the public understanding of estrogen and bone — a study with significant design problems was misread for two decades, and an entire generation of women were steered away from a therapy that, used properly, is one of the most effective tools we have for preserving the skeleton. The picture is more nuanced now, the data is much better, and the conversation deserves to catch up.
What estrogen actually does for bone
Bone is not static tissue. It is constantly being remodeled — osteoclasts breaking down old bone, osteoblasts laying down new bone. Through reproductive years that cycle is roughly balanced. Bone density peaks in the late 20s, holds through the 30s, and begins a gradual decline that becomes much steeper at menopause.
Estrogen is the central regulator of that balance. It directly suppresses osteoclast activity and supports osteoblast survival. When estrogen declines at menopause, osteoclast activity rises and bone resorption outpaces formation. For the average woman, that loss runs about 2 percent per year for the first five years post-menopause and around 1 percent per year thereafter.
That 5 to 10 percent loss in the first five years is what produces the osteopenia we see on early postmenopausal DEXAs. By 80, a woman who never received any intervention has typically lost 30 to 40 percent of her peak bone mass — and most hip fractures in older women are happening on the back end of that trajectory, not because of a single fall but because the underlying bone could no longer tolerate normal forces.
Estrogen replacement, started in the early postmenopausal window, prevents the steep early loss. It does not just slow it — it largely halts it. Bone mineral density at the spine and hip stabilizes or improves modestly. The difference between a woman who started transdermal estradiol at 51 and one who did not, twenty years later, can be measured in fracture risk that differs by a factor of two or three.
Testosterone supports osteoblast function and contributes to the lean mass that drives mechanical loading on the skeleton. In women it has been understudied in this context, but the data we do have is consistent — women on testosterone alongside estrogen show better bone density outcomes than women on estrogen alone. Progesterone has its own bone story; receptors are present on osteoblasts, and the limited data suggests it supports bone formation.
The window of opportunity
The timing of when hormone therapy starts changes the picture. The studies that have separated women who started hormone therapy within ten years of menopause from women who started later show consistently better cardiovascular and bone outcomes for the early-start group.
For bone specifically, the early-start advantage is substantial. A woman who begins transdermal estradiol within the first three to five years of menopause largely prevents the steep early loss. A woman who begins ten or fifteen years out can still benefit, but she is now working to recover ground that has already been lost rather than protecting what was there.
This is one of the reasons I push back hard on the idea that hormone therapy is something to delay until symptoms are unbearable. By the time the symptoms are unbearable, the bone window has often closed in a meaningful way. The decision about whether to start hormone therapy in early menopause should consider the bone trajectory, not just the hot flash burden.
For patients who are already five, ten, or more years out from menopause and have not been on hormone therapy, the conversation shifts. The risk-benefit calculation looks different in that group, and a careful workup is more important than ever — we are weighing the bone benefit, the cardiovascular consideration, and the patient's individual risk profile rather than assuming the early-start framework still applies.
What I look for in the workup
When I evaluate a postmenopausal patient with bone density on the table, the workup goes well beyond a single estradiol level. The labs and assessments I want:
A baseline DEXA scan if one has not been done in the last two years. T-score at the lumbar spine and femoral neck are the headline numbers, but I also look at the Z-score, the trabecular bone score where available, and any prior DEXA for trajectory.
A full sex hormone panel — estradiol, progesterone, free and total testosterone, SHBG, DHEA-S. A patient cannot be optimally dosed without knowing where her current values are.
A full thyroid panel including TSH, free T3, free T4, and antibodies. Hyperthyroidism — even subclinical — accelerates bone loss significantly.
Not sure where to start?
The Start Here pathway walks you through the most common entry points and helps you decide which consultation type is the right fit. Five minutes of self-assessment can save you a wrong-direction conversation.
Vitamin D, calcium, magnesium, and phosphorus. Vitamin D below 40 ng/mL needs correction; below 30 needs aggressive correction. The hormone work will not produce optimal bone outcomes against a backdrop of vitamin D deficiency.
PTH and ionized calcium when secondary hyperparathyroidism is on the table. This is one of the most under-recognized contributors to bone loss in postmenopausal women, and a single PTH paired with a calcium can sort it out.
CTX or P1NP — bone turnover markers — when I want a closer look at where the patient sits on the resorption-formation balance. DEXA is slow. Turnover markers move within months and let me know whether the dose is doing what it is supposed to.
Smoking history, alcohol intake, glucocorticoid exposure, prior fragility fractures, family history. All of it goes into the picture.
How I dose for bone protection
Bone protection is not the same dosing target as symptom relief. A transdermal estradiol dose that controls hot flashes may or may not be enough to support bone, and I want to verify rather than assume.
For most postmenopausal women using bone protection as a primary or significant goal, I am aiming for a serum estradiol in the range of approximately 50 to 100 pg/mL on the patch — verified by a draw timed appropriately to the patch cycle. Below 40 pg/mL, the bone protection is partial. Above 100 pg/mL on average, we are pushing into territory where the marginal bone benefit shrinks and other considerations come into play.
Transdermal delivery is my preferred route in this context. It bypasses hepatic first-pass effect, has a more favorable thrombosis profile than oral estrogen, and produces stable serum levels. For some patients, Biote pellet therapy is a good fit — it produces stable serum estradiol over a three-to-four-month window and reduces the daily-management burden. For other patients, the patch or a compounded transdermal cream is a better starting point because of the titratability.
Testosterone enters the conversation when free testosterone is low and the broader picture supports it. The dosing for women is a fraction of male dosing — typically 4 to 8 mg subcutaneous weekly of testosterone cypionate, or a comparable dose via cream or pellet. The bone benefit is real, and the additional benefits to lean mass, libido, and energy are usually welcome.
Progesterone — bioidentical, oral micronized, taken at bedtime — is part of the regimen for any woman with an intact uterus, both for endometrial protection and for the sleep and mood support it provides.
Hormone optimization for bone is a long-term framework, not a short course. The decision to continue therapy past the conventional five-year window is made with the patient annually, weighing the labs, the DEXA trajectory, the cardiovascular picture, and the patient's preferences and risk profile.
What I tell patients about long-term safety
The Women's Health Initiative finding that drove the fear of long-term hormone therapy was based largely on women who started hormone therapy a decade or more after menopause, on oral conjugated equine estrogen with a synthetic progestin. The risk profile of that intervention is not the same as the risk profile of transdermal estradiol with bioidentical progesterone started in the early postmenopausal window. The reanalyses of the WHI data, the timing-hypothesis follow-up studies, and the more recent meta-analyses all point to a substantially more favorable picture for the modern protocols when used in the appropriate population.
I am not dismissive of the risks. Breast cancer history, personal or strong family clotting history, active liver disease, and a few other situations are genuine contraindications and I will tell patients straight when they apply. The breast cancer conversation in particular gets nuanced and individual — for some patients the risk-benefit calculation favors hormone therapy and for some it does not, and that conversation cannot be reduced to a slogan.
What I am dismissive of is the blanket "estrogen is dangerous" message that scared a generation of women away from a therapy that, used carefully, would have protected their bones, their cardiovascular health, and their cognitive function for decades.
The next step
If you are in the early postmenopausal window and the bone conversation has not been part of your hormone therapy discussion, that is the conversation worth having. If you are further out and have a DEXA showing osteopenia or worse, the workup needs to be comprehensive before any decision is made about hormone therapy versus bisphosphonates versus the combinations that some patients need.
Bring your most recent DEXA if you have one. Bring any prior hormone labs. Bring the medication list, the supplement list, and the family history. The first visit covers the full workup; the second visit is the data review and the plan.
You can book a consultation at either the Columbus location or the Warner Robins location. For patients who want a structured starting point before booking, the comprehensive lab work pathway can sort out which consultation type fits.
The bone trajectory is decided in the years immediately after menopause. The interventions that matter most are the ones started while the window is open. That is the conversation worth having sooner rather than later.
Medical disclaimer: This article is for educational purposes only and does not constitute medical advice. Individual clinical decisions should be made in consultation with a qualified healthcare provider following appropriate evaluation. References to specific treatments, dosing, or protocols are informational.
Travis spent 17+ years in high-acuity clinical medicine — emergency, cardiac ICU, and cath lab — before founding Revitalize. He is a Certified Platinum Biote hormone therapy provider, the published author of You're Not Broken — You're Unbalanced, and the founder of the Rebuild Metabolic Health Institute. His clinical writing reflects the same precision he brought to critical care: specific, honest, and built around what actually works.
Ready to talk it through with a clinician?
Book online or call either Georgia location. Every visit starts with a consultation.